Dexcom G7 Canada Authorization
Health Canada Authorizes Dexcom G7 15-Day CGM for Canadian Adults with Diabetes, Offering Extended Wear
Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for Canadian adults living with diabetes, according to Financial Post. The device delivers real-time glucose readings for an industry-leading 15.5 days — longer than any other CGM system currently on the market.
The system is cleared for people 18 years and older. However, National Post notes the product is not yet available for purchase in Canada, meaning patients will need to wait before they can get it at a pharmacy or through their care provider.
What Makes the G7 15 Day Different From Earlier Models
The original Dexcom G7 wore for 10 days. This new version stretches that to 15.5 days, including a 12-hour grace period after the main session ends. That means users change their sensor fewer times each month — roughly twice instead of three times, according to Montreal Gazette.
The sensor is small, discreet, and designed to be painless to insert. Dexcom says it is the most accurate CGM system currently authorized by Health Canada. A CGM — short for continuous glucose monitor — checks blood sugar automatically throughout the day and night without finger pricks.
Fewer Sensor Changes Mean Less Disruption for Patients
For people managing diabetes, changing a sensor is a routine but time-consuming task. Moving from a 10-day to a 15.5-day wear window cuts the number of monthly changes by roughly one-third. That is a meaningful difference for patients who rely on CGM data every hour of every day, Shoreline Beacon reported.
The device sends real-time glucose data directly to a smartphone or receiver. Users and their doctors can track trends, spot dangerous highs and lows, and act faster. Dexcom has been building CGM technology for over 25 years, according to Stratford Beacon Herald.
Health Canada Clears Device But Sale Date Still Unknown
Health Canada authorization means the device has passed Canada's safety and effectiveness review. But authorization is not the same as availability. The Observer confirmed the G7 15 Day is not yet for sale, and Dexcom has not announced a launch date for the Canadian market.
Patients interested in the device should speak with their diabetes care team. Coverage through provincial drug plans or private insurance has also not yet been confirmed. Canadians currently using the standard Dexcom G7 can continue using that system in the meantime, according to Pincher Creek Echo.
Dexcom Expands Its Lead in the Global CGM Market
Dexcom describes itself as the global leader in glucose biosensing. The G7 15 Day builds on the success of the G7, which is already sold in dozens of countries. The Canadian authorization follows similar approvals in other markets, according to CA MarketScreener.
The CGM market is growing fast as more people are diagnosed with both Type 1 and Type 2 diabetes. Longer-wear sensors are seen as a key way to improve patient experience and reduce care costs. The G7 15 Day positions Dexcom ahead of rivals still offering 10- to 14-day wear windows, Financial Post noted.
Sentiment
NeutralPublishers
12
Articles
12
Reach
12
